The impact of pharmaceuticals on the decline of cardiovascular mortality in Germany

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 10, 2007, Pages 1167-1176

  Häussler, Bertram ^a   Schiffhorst, Guido ^a   Gothe, Holger ^a   Hempel, Elke ^a  

^a IGES Institut für Gesundheits und Sozialforschung GmbH   (Germany)

Author keywords

Cardiovascular mortality; Innovative medicines; Surgical interventions

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; GERMANY; HEALTH BEHAVIOR; HUMAN; LIFESTYLE MODIFICATION; LINEAR REGRESSION ANALYSIS; MORTALITY; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ASPIRIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GERMANY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 35648940782     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1428     Document Type: Article

References (21)

1. McKeown T. The role of medicine: dream, mirage, or nemesis? Nuffield Provincial Hospitals Trust, 1976.
2. Bunker JP. Medicine's core values (Letter). BMJ 1994; 309(6969): 1657.
3. Morrison I, Smith R. The future of medicine. BMJ 1994; 309(6962): 1099-1100.
4. Macinko J, Startield B, Shi L. The contribution of primary care systems to health outcomes within Organization for Economic Cooperation and Development (OECD) countries, 1970-1998. Health Serv Res 2003; 38(3): 831-865.
5. Shi L, Macinko J, Starfield B, et al. The relationship between primary care, income inequality, and mortality in US States, 1980-1995. J Am Board Fam Pract 2003; 16(5): 412-422.
6. Miller RD, Frech HE. Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 2000; 18(1): 33-45.
7. Frech HE, Miller RD. The effects of pharmaceutical consumption and obesity on the quality of life in the organization of economic cooperation and development (OECD) countries. Pharmacoeconomics 2004; 22(2): 25-36.
8. Bots ML, Grobbee DE. Decline of coronary heart disease mortality in The Netherlands from 1978 to 1985: contribution of medical care and changes over time in presence of major cardiovascular risk factors. J Cardiovasc Risk 1996; 3(3): 271-276.
9. Capewell S, Morrison CE, McMurray JJ. Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. Heart 1999; 81(4): 380-386.
10. Capewell S, Beaglehole R, Seddon M, et al. Explanation for the decline in coronary heart disease mortality tares in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102(13): 1511-1516.
11. Unal B, Crichley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 2004; 109(9): 1101-1107.
12. Lichtenberg FR. Do (more and better) drugs keep people out of hospitals? Am Econ Rev, American Economic Association 1996; 86(2): 384-388.
13. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 2001; 20(5): 241-251.
14. Lichtenberg FR. Availability of new drugs and Americans' ability to work. J Occup Environ Med 2005; 47(4): 373-380.
15. Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. Int J Health Care Finance Econ 2005; 5(1): 47-73.
16. Chiang CL. The Life Table and its Applications. Robert E. Krieger Publishing: Malabar, FL, 1984.
17. Bruckenberger E. 14. Herzbericht 2001 mit Transplantationschirurgie (Hannover: Niedersächsisches Ministerium für Frauen, Arbeit und Soziales).
18. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47(11): 1245-1251.
19. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000; 29: 891-898.
20. Scandinavian Simvastatin Survival Study Group, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
21. Hunink GM, Goldman L, Tosteson AN, et al. The recent decline in mortality from coronary heart disease, 1980-1990.The effects of secular trends in risk factors and treatment. JAMA 1997; 277(7): 535-542.